iolanda capone

Medicine & Life Sciences

1. Afatinib 100%
2. ErbB Receptors 62%
3. Colorectal Neoplasms 52%
4. Abiraterone Acetate 51%
5. regorafenib 51%
6. Panitumumab 48%
7. Salivary Gland Neoplasms 47%
8. Ipilimumab 46%
9. O-(6)-methylguanine 45%
10. Nivolumab 44%
11. Anaplastic Lymphoma Kinase 43%
12. Temozolomide 40%
13. Mutation 39%
14. Methyltransferases 36%
15. Progression-Free Survival 36%
16. Castration 36%
17. Androgen Receptors 35%
18. Therapeutics 34%
19. Microsatellite Repeats 34%
20. Datasets 29%
21. Salivary Glands 28%
22. Neoplasms 27%
23. abiraterone 24%
24. Circulating Tumor DNA 20%
25. Non-Small Cell Lung Carcinoma 20%
26. Androgens 19%
27. DNA 18%
28. Carcinoma 18%
29. Survival 16%
30. Exons 15%
31. Liquid Biopsy 13%
32. Heterografts 12%
33. Response Evaluation Criteria in Solid Tumors 11%
34. Gonadotropin-Releasing Hormone 10%
35. Metformin 10%
36. Atlases 10%
37. Clinical Decision-Making 9%
38. Safety 9%
39. Hypophysitis 8%
40. Protein-Tyrosine Kinases 8%
41. Survival Rate 8%
42. Epigenomics 8%
43. Disease Progression 7%
44. entrectinib 7%
45. Proof of Concept Study 6%
46. Supraventricular Tachycardia 6%
47. Genome 6%
48. CH5424802 6%
49. Genetic Counseling 5%
50. Cetuximab 5%